• Home
  • About Us
  • Services
  • Telperian Foundation
  • Resources
  • Contact

    About Us

    Pioneering technological innovations in ML-AI that seek to curtail the expenses in developing drugs through the automation and democratization of advances in biostatistics and data science. Our solutions have attracted substantial attention from leading biopharma companies and prestigious cancer research centers. The TELPERIAN platforms provide powerful technological advantage for drug developers yielding gains in efficiency with reduced staffing burden.
    The Team

    The team behind Telperian

    Rick Landin

    Dr. Landin has over 25 years of drug development experience ranging from preclinical to post-commercialization. His therapeutic areas of expertise include precision medicine, oncology, asthma and allergy, migraine, insomnia, depression, general anxiety disorder, multiple sclerosis, lupus, and rheumatoid arthritis. During his time in the industry, Dr. Landin has established a history of building, managing and leading Biometrics organizations in large R&D (Marion Merrell Dow, Eli Lilly, Biogen), small-to-midsize-pharma (IDEC, Neurocrine), as well as pre-commercialization (Ambit, Ignyta, La Jolla Pharmaceuticals). In addition, he has served and led cross functional, multi-corporate teams, leading to regulatory submission and approval of multiple products. Dr. Landin holds a Ph.D. is Statistics from Texas A&M University. Since graduating from Texas A&M, Dr. Landin has been committed to the practical application of statistical theory for the advancement of drug development, with successes including the following: development of the Theory of Selective Score Inflation to redesign depression studies, the creation of innovative endpoints for the measure of Sleep Maintenance, innovative data presentation of QTc data, and most recently serving as a catalyst in the development of a precision medicine toolbox based on advances in applied math/machine learning.

    Adam Sharp

    Mr. Sharp has over 20 years as a statistical programming and data standards consultant. As Chief Executive Officer of SimulStat, Inc., a boutique Contract Research Organization, Mr. Sharp has extensive experience providing efficient, scalable operational and financial systems to support growth and profitability. SimulStat has served multiple clients across pharma, biotech, academia, and medical devices companies, and has a proven record of implementing complex CDISC mappings, as well as navigating those mappings through FDA submission guidelines. Mr. Sharp holds a BS in Statistics from Iowa State University.

    Ryan Hafen

    Dr. Hafen is a data scientist with expertise and interest in exploratory data analysis, data visualization, computational statistics, statistical model building, and machine learning on large, complex datasets. Dr. Hafen has worked as a research scientist and consultant in many fields, including global health, cyber security, power systems engineering, and the physical and biological sciences. He has a passion for building tools that enable greater data fluency. He holds a Ph.D. in statistics from Purdue University.

    Daniel Hargrove

    Chief Strategy Officer
    Mr Hargrove is a biotech entrepreneur, investor, and lawyer. He was co-founder and past president of Cancer Insight, LLC (now LumaBridge), which is a full-service clinical Contract Research Organization that develops immunotherapeutics. Mr. Hargrove led Cancer Insight from formation (2012) to acquisition (2021) by the private equity firm Summit Partners. He is the co-founder of PalloV, LLC, a clinical-stage drug company developing novel immunotherapeutics. Mr. Hargrove is the former CEO of Emtora Bio sciences where he led the company’s efforts to translate its lead drug candidate from the bench to its first-in-human clinical trial; earned a multimillion dollar investment from the Cancer Prevention & Research Institute of Texas (CPRIT), which was matched by private investors; obtained orphan drug designation from FDA for its lead drug candidate; and commenced a phase II study in the rare disease of familial adenomatous polyposis (ongoing). Emtora is soon to start its first registrational study and recently was awarded an additional $17.7 Million from CPRIT. Mr. Hargrove was the initial investor of Slope.io, Inc. Slope has created a sophisticated clinical trial execution platform that provides a systematic, real-time solution for complete visibility of clinical supply progress for sponsors, CROs, clinical research sites, and labs — all in one central location. In 2021, NEA invested $20 Million into Slope. Mr. Hargrove serves on Slope’s Board of Directors and Business Advisory Board. Mr. Hargrove is a former active-duty Army officer, having served with the 10th Mountain Division (Light Infantry) and deployed to the Middle East with the 82nd Airborne Division. As a reservist, Mr. Hargrove served as a Professor of Law at the U.S. Army JAG School from 2004 to 2012 and reserve staff judge advocate (general counsel) of two major Air Force commands. He retired from the Reserve in 2018 with the rank of Lieutenant Colonel. Mr. Hargrove serves on CPRIT’s Product Development Advisory Committee and the External Advisory Committee for the Texas Medical Center – Accelerator for Cancer Therapeutics. He and his wife, Susie Hargrove, JD, are biotech investors through their firm, Texas BioTech Ventures, LLC.

    Mike Kane

    Dr. Kane is an Assistant Professor of Biostatistics at Yale University. He was awarded John M. Chambers Statistical Software award for The Bigmemory Project. In 2012, named Co-PI for a grant in DARPA’s XDATA program, part of the Obama Administrations Big Data Initiative. Advisor for AT&T Labs Research on design and develop of petabyte-scale analysis infrastructure. Authored A Computational Approach to Statistical Learning. Expertise in the development of methods in statistical and machine learning with focuses on applications in clinical trials and population-scale human mobility.

    David Hong

    Dr. Hong is a Full Professor, Deputy Chair of the Department of Investigational Cancer Therapeutics, Associate Vice President of Clinical Research at MD Anderson Cancer Center. Extensive expertise in drug development for combination therapy and patient populations with other major comorbidities. Has published extensively on the clinical investigation of combination drug therapy, including multiple studies involving antibody therapeutics and/or immuno-oncology drugs. Recently his research endeavors have focused on developing personalized therapies for patients, whose tumors bear specific genetic mutations/amplifications and combining targeted therapies with immunotherapies.

    Brian Hobbs

    Dr. Brian Hobbs, Scientific Advisor and Founder of Telperian, completed a doctoral degree in biostatistics at the University of Minnesota and then joined The University of Texas MD Anderson as an Assistant Professor of biostatistics. His expertise spans Bayesian methodology and trial design as well as clinical and translational oncology. Dr. Hobbs was promoted to Associate in 2017, and then recruited to Cleveland Clinic to found a Section of Cancer Biostatistics. He joined The University of Texas Dell Medical School in August 2020 as a tenured Associate Professor. The Eastern North American Region of International Biometric Society selected his thesis paper for the John Van Ryzin Award in 2010. In 2016, Dr. Hobbs was selected by The University of Minnesota for the Emerging Leader Award, an honor bestowed on alumni on the basis of impactful contributions within 10 years of graduating from one of The School of Public Health’s 20 programs. Recognized as an expert in clinical oncology research methodology, in 2017 Dr. Hobbs was invited to lead the publication of National Cancer Institute’s Clinical Trials Design Task Force with the goal of providing national, consensus recommendations for first-in-human cancer drug trials that use seamless designs. In 2019, Dr. Hobbs was invited to describe recent advances and current issues with basket trial designs in the Journal of Clinical Oncology Precision Oncology. In 2020, he was invited to contribute to an article for Nature Reviews Clinical Oncology describing the current state of tumor agnostic trials. Dr. Hobbs has served as a scientific advisor to Amgen, STCube, Bayer HealthCare Pharmaceuticals Inc. and consultant to Pfizer.